Boxer Capital LLC held its position in shares of Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) during the first quarter, Holdings Channel reports. The fund owned 234,220 shares of the company’s stock at the end of the first quarter. Syndax Pharmaceuticals accounts for 0.7% of Boxer Capital LLC’s holdings, making the stock its 19th largest position. Boxer Capital LLC’s holdings in Syndax Pharmaceuticals were worth $3,213,000 at the end of the most recent reporting period.
Several other institutional investors also recently made changes to their positions in SNDX. C WorldWide Group Holding A S bought a new position in shares of Syndax Pharmaceuticals during the first quarter valued at $163,000. Trexquant Investment LP bought a new position in shares of Syndax Pharmaceuticals during the first quarter valued at $283,000. TIAA CREF Investment Management LLC raised its position in shares of Syndax Pharmaceuticals by 36.2% in the first quarter. TIAA CREF Investment Management LLC now owns 22,924 shares of the company’s stock valued at $315,000 after buying an additional 6,091 shares in the last quarter. Oppenheimer & Co. Inc. bought a new position in shares of Syndax Pharmaceuticals during the first quarter valued at $365,000. Finally, Elkfork Partners LLC bought a new position in shares of Syndax Pharmaceuticals during the fourth quarter valued at $204,000. Hedge funds and other institutional investors own 54.45% of the company’s stock.
Syndax Pharmaceuticals, Inc. (SNDX) traded up 4.09% during midday trading on Friday, reaching $11.20. 175,478 shares of the company’s stock traded hands. The firm’s 50-day moving average is $10.83 and its 200 day moving average is $10.28. The firm’s market cap is $204.46 million. Syndax Pharmaceuticals, Inc. has a 52-week low of $6.31 and a 52-week high of $18.03.
Syndax Pharmaceuticals (NASDAQ:SNDX) last issued its earnings results on Monday, May 8th. The company reported ($0.71) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.74) by $0.03. The business had revenue of $0.31 million during the quarter, compared to analysts’ expectations of $0.31 million. Syndax Pharmaceuticals had a negative net margin of 3,861.72% and a negative return on equity of 52.82%. Equities research analysts expect that Syndax Pharmaceuticals, Inc. will post ($3.63) earnings per share for the current fiscal year.
COPYRIGHT VIOLATION WARNING: “Boxer Capital LLC Continues to Hold Position in Syndax Pharmaceuticals, Inc. (SNDX)” was posted by sleekmoney and is owned by of sleekmoney. If you are viewing this report on another site, it was illegally copied and republished in violation of United States and international copyright & trademark legislation. The correct version of this report can be read at https://sleekmoney.com/boxer-capital-llc-continues-to-hold-position-in-syndax-pharmaceuticals-inc-sndx/1916379.html.
A number of equities research analysts recently weighed in on SNDX shares. Nomura started coverage on shares of Syndax Pharmaceuticals in a report on Wednesday, March 1st. They issued a “buy” rating on the stock. Instinet started coverage on shares of Syndax Pharmaceuticals in a report on Wednesday, March 1st. They issued a “buy” rating and a $27.00 target price on the stock. Oppenheimer Holdings, Inc. set a $25.00 target price on shares of Syndax Pharmaceuticals and gave the stock a “buy” rating in a report on Saturday, March 4th. FBR & Co started coverage on shares of Syndax Pharmaceuticals in a report on Thursday, March 16th. They issued an “outperform” rating and a $27.00 target price on the stock. Finally, Cowen and Company started coverage on shares of Syndax Pharmaceuticals in a report on Friday, March 24th. They issued an “outperform” rating on the stock. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and nine have issued a buy rating to the company. Syndax Pharmaceuticals has an average rating of “Buy” and a consensus price target of $23.75.
In other Syndax Pharmaceuticals news, insider Peter Ordentlich sold 5,000 shares of Syndax Pharmaceuticals stock in a transaction dated Wednesday, May 17th. The shares were sold at an average price of $15.00, for a total value of $75,000.00. Following the completion of the transaction, the insider now directly owns 5,000 shares of the company’s stock, valued at $75,000. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. 24.10% of the stock is currently owned by insiders.
Syndax Pharmaceuticals Company Profile
Syndax Pharmaceuticals, Inc (Syndax) is a clinical stage biopharmaceutical company focused on developing a pipeline of combination therapies in multiple cancer indications. The Company’s product candidate, entinostat, which was granted Breakthrough Therapy designation by the FDA following positive results from its Phase IIb clinical trial, ENCORE 301, is being evaluated in a Phase III clinical trial for advanced hormone receptor positive breast cancer.
Want to see what other hedge funds are holding SNDX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX).
This story was originally published by sleekmoney (https://sleekmoney.com) and is the sole property of sleekmoney. If you are reading this article on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. You can view the original version of this story at https://sleekmoney.com/boxer-capital-llc-continues-to-hold-position-in-syndax-pharmaceuticals-inc-sndx/1916379.html
Receive News & Ratings for Syndax Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Syndax Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.